Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEE-REX: Dexamethasone-eluting cochlear implant in sensorineural hearing loss
NCT06598059Active, not recruiting
- Sponsor
- Cochlear
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of dexamethasone in sensorineural hearing loss (SNHL), sponsored by Cochlear. Primary endpoints: Mean monopolar 1 plus 2 impedances at 16 weeks and Mean change in word recognition score at 16 weeks. Started Jan 2025; status: active, not recruiting.
02
Drugs
dexamethasone
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT06598059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598059.